We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+5.45%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$3.11B
AUM Growth
+$2.21M
Cap. Flow
-$39.8M
Cap. Flow %
-1.28%
Top 10 Hldgs %
35.29%
Holding
188
New
16
Increased
26
Reduced
40
Closed
17

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$35.7M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$32.2M
3
MRNA icon
Moderna
MRNA
+$25.5M
4
DHR icon
Danaher
DHR
+$16.7M
5
RMD icon
ResMed
RMD
+$15.7M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$25.3M
2
EXAS
Exact Sciences
EXAS
+$21.5M
3
CTLT
CATALENT, INC.
CTLT
+$19.2M
4
XRAY icon
Dentsply Sirona
XRAY
+$17.1M
5
CI icon
Cigna
CI
+$16.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.33%
2 Real Estate 2.82%
3 Industrials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JAZZ icon
51
Jazz Pharmaceuticals
JAZZ
$15.9B
$14.9M 0.48%
117,315
+3,256
+3% +$428K
LH icon
52
Labcorp
LH
$25B
$13.9M 0.45%
51,381
-58,799
-53% -$14.6M
ARGX icon
53
argenx
ARGX
$53.4B
$13.5M 0.43%
38,456
– –
NVO
54
Novo Nordisk
NVO
$208B
$13.3M 0.43%
236,698
+45,292
+24% +$2.45M
KRTX
55
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$13.2M 0.42%
100,458
– –
VTR icon
56
Ventas
VTR
$48B
$12.7M 0.41%
248,131
– –
ACH
57
Accendra Health
ACH
$237M
$12.5M 0.4%
288,167
-6,800
-2% -$267K
ITCI
58
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$12.4M 0.4%
236,447
-87,954
-27% -$3.69M
MRTX
59
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$12.3M 0.4%
83,784
– –
NVS icon
60
Novartis
NVS
$297B
$11.9M 0.38%
136,225
– –
RARE icon
61
Ultragenyx Pharmaceutical
RARE
$2.45B
$11.8M 0.38%
140,726
– –
BMRN icon
62
BioMarin Pharmaceuticals
BMRN
$11.6B
$11.3M 0.36%
128,004
– –
MTD icon
63
Mettler-Toledo International
MTD
$28.6B
$11.3M 0.36%
6,650
– –
BDX icon
64
Becton Dickinson
BDX
$45.6B
$10.9M 0.35%
44,390
– –
QURE icon
65
uniQure
QURE
$3.03B
$10.8M 0.35%
521,693
+284,685
+120% +$8.16M
NBIX icon
66
Neurocrine Biosciences
NBIX
$16.8B
$10.6M 0.34%
124,609
– –
WAT icon
67
Waters Corp
WAT
$37B
$10.6M 0.34%
28,461
– –
DNLI icon
68
Denali Therapeutics
DNLI
$3.65B
$9.92M 0.32%
222,420
– –
CRBU icon
69
Caribou Biosciences
CRBU
$145M
$9.88M 0.32%
699,377
– –
MPT
70
Medical Properties Trust
MPT
$2.77B
$9.73M 0.31%
411,743
– –
BHVN
71
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$9.67M 0.31%
70,176
-20,623
-23% -$2.62M
ADPT icon
72
Adaptive Biotechnologies
ADPT
$3.59B
$9.48M 0.3%
337,722
– –
DOC
73
DELISTED
PHYSICIANS REALTY TRUST
DOC
$9.34M 0.3%
495,733
– –
APLS
74
DELISTED
Apellis Pharmaceuticals
APLS
$9.26M 0.3%
195,820
– –
NVAX icon
75
Novavax
NVAX
$1.2B
$9.13M 0.29%
63,800
-87,691
-58% -$15.1M
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Tekla Capital Management held 188 positions worth $3.11B, up 0.07% from $3.11B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Tekla Capital Management's Q4 2021 filing shows 16 new, 26 increased, 40 reduced and 17 closed positions. Its largest new stake was AMN Healthcare: 61,201 shares worth $7.49M. The largest sale was Biogen, an estimated $25.3M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q4 2021 buy was AMN Healthcare: 61,201 shares worth $7.49M.
  • Tekla Capital Management added most to Pfizer in Q4 2021, an estimated $35.7M increase.
  • Tekla Capital Management's biggest Q4 2021 reduction was Biogen, cutting an estimated $25.3M.
  • Tekla Capital Management fully exited Exact Sciences in Q4 2021, selling an estimated $21.5M.
  • Tekla Capital Management's ten largest holdings make up 35% of its $3.11B portfolio in Q4 2021.
  • Tekla Capital Management opened 16 new positions and closed 17 in Q4 2021.
  • Tekla Capital Management's portfolio value rose 0.07% quarter-over-quarter to $3.11B.

Based on Tekla Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.